BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Trump Signs Order to Cut Routine Childhood Vaccines 
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 
3 clinical-grade skincare creams you really shouldn’t buy online 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Apple Extends Qualcomm Patent Licensing Deal 
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
SpaceXAI to Double Nvidia Chips at Colossus 2 by Year-End 
Add as a preferred source on Google
Novo Nordisk has agreed to pay up to €1.165 billion ($1.37 billion) to license drug-delivery technology from Swedish biotechnology company Nanexa, potentially paving the way for longer-lasting obesity and diabetes treatments that require fewer injections.
The exclusive global licensing agreement gives Novo Nordisk access to Nanexa’s PharmaShell platform, a drug-delivery technology designed to enable the controlled release of medicines over extended periods. The partnership will cover as many as five development programs focused on obesity, type 2 diabetes and other cardiometabolic diseases.
If successful, the technology could allow some Novo Nordisk treatments that are currently administered weekly to be given once a month or even once every three months. Longer dosing intervals could improve convenience for patients and potentially strengthen Novo Nordisk’s position in the rapidly expanding obesity and diabetes drug markets.
Under the agreement, Novo Nordisk will pay Nanexa up to €615 million through upfront payments and development and regulatory milestones. Additional payments tied to commercial sales milestones could bring the total value of the deal to €1.165 billion.
Nanexa will also be entitled to low-single-digit royalties on worldwide net sales of products developed using its PharmaShell technology.
Novo Nordisk will take responsibility for the global development and commercialization of treatments arising from the partnership. The Danish pharmaceutical company is already one of the world’s leading developers of obesity and diabetes medicines, making longer-acting formulations an important potential area for expanding its cardiometabolic portfolio.
For Nanexa, the licensing agreement provides a major opportunity to deploy its drug-delivery platform across multiple large-scale development programs backed by Novo Nordisk’s global clinical and commercial infrastructure.
The deal comes as pharmaceutical companies increasingly explore longer-acting drug formulations to make chronic treatments easier for patients to use. In obesity and type 2 diabetes, where injectable therapies may need to be taken for extended periods, reducing dosing frequency could become an important factor in future treatment development.
